TCRT Stock Explodes As Velaris Deal Reshapes Alaunos

Alaunos Therapeutics Inc. stocks have been trading up by 27.06 percent amid heightened optimism over its cancer therapy pipeline.

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TCRT

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

Key Takeaways

Alaunos Therapeutics completed its buyout of Velaris Therapeutics, gaining a pipeline targeting pulmonary arterial hypertension and related cardiopulmonary diseases.
The company raised about $350M in a private placement, extending its cash runway into 2029 and funding several drug candidates.
Management plans to push new lead asset VLR199 for pulmonary arterial hypertension through early clinical proof-of-concept with this capital.
Following the deal and financing, TCRT shares ripped roughly 126% in one report.
Another report pegged the same news as driving a ~225% surge in TCRT on extremely heavy trading volume.

Live Update At 09:17:34 EDT: On Wednesday, October 14, 2026 Alaunos Therapeutics Inc. stock [NASDAQ: TCRT] is trending up by 27.06%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TCRT just flipped its story with one massive catalyst, but the base financials still matter for traders. Alaunos Therapeutics generated only about $5,000 in revenue over the last period, which is tiny even for a micro-cap biotech. With a price-to-sales ratio near 957, the market is clearly trading TCRT on future potential, not current sales.

Margins show how early-stage this story is. Alaunos posts a pretax profit margin around -3,347%, reflecting heavy research and overhead against almost no revenue. Return on equity and return on assets are deeply negative as well, classic for a development-stage biotech still burning cash to fund trials.

More Breaking News

The latest quarterly report shows TCRT losing about $952,000, with operating cash flow around -$300,000 and only $124,000 in cash on hand at period end. A current ratio of 0.8 and working capital of -$198,000 signaled a tight cash position before the Velaris deal and $350M raise. That is exactly why this new financing round is such a big pivot for Alaunos Therapeutics and a key focus for short-term trading.

Why Traders Are Watching TCRT After The Velaris Deal

This is the type of setup momentum traders hunt. Alaunos Therapeutics closed its acquisition of Velaris Therapeutics and, in the same breath, locked in about $350M in private placement funding. For a company that previously ended a quarter with $124,000 in cash, that is a complete reset of the balance sheet and the story.

The deal hands TCRT a new pipeline built around ActRII‑Fc ligand traps and biologics aimed at pulmonary arterial hypertension and related cardiopulmonary diseases. The headline program, VLR199, now sits at the center of the Alaunos Therapeutics pitch. Management expects this cash pile to fund operations into 2029 and push several candidates through proof-of-concept and initial regulatory filings. For biotech traders, that kind of runway reduces near-term financing risk, which often caps upside in names like TCRT.

The tape confirms how big this shift was for trading. One report tied the news to a roughly 126% spike in TCRT shares. Another cited about a 225% surge on extremely heavy volume as the market re-rated the stock. The daily chart backs up the story: TCRT jumped from a prior close near $1.05 to a high above $4.30 on 2026/10/13 before finishing around $3.03. That is multi-bagger action in a single session, and the intraday five‑minute chart shows constant whipsaws between $3.40 and just under $4.20 as momentum players piled in and out. For active traders, Alaunos Therapeutics has moved from sleepy micro-cap to full-on momentum ticker almost overnight.

Conclusion

For TCRT, the Velaris Therapeutics acquisition plus the $350M private placement is a clear turning point. Alaunos Therapeutics now shifts from a cash‑strapped oncology name with minimal revenue to a better‑funded cardiopulmonary platform aiming at pulmonary arterial hypertension. A funded runway into 2029 gives management room to chase proof-of-concept on VLR199 and other assets without immediately knocking on the capital markets door again. That matters because dilution fear is a constant overhang in small biotech trading.

At the same time, the financials remind traders what TCRT still is: a pre-revenue, loss‑making biotech whose valuation now leans heavily on future trial success. Profitability metrics remain deeply negative, and the enterprise value will now embed expectations for the Velaris pipeline. After a one‑day move that saw Alaunos Therapeutics jump more than 100%, and in one report over 200%, the bar for execution just moved higher.

For day and swing traders tracking TCRT, this is now a pure sentiment and catalyst play. Watch volume, intraday trend shifts, and news around VLR199 and other Velaris programs. As Tim Sykes likes to say, “Trade the price action, not the story.” In the same spirit of disciplined trading, As Tim Bohen, lead trainer with StocksToTrade says, “I never chase price. The best opportunities allow me to enter on my terms, not when I’m feeling pressured.”. The story on Alaunos Therapeutics just got a lot more exciting, but the chart will still tell you when to enter, when to scale, and when to walk away. All of this is for educational and research purposes only, and every trader must do their own homework before making any decisions.

This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.

Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.

Check out our quick startup guide for new traders!

Ready to build your watchlists? Check out these curated lists:

Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.

Start Your Trial Now!